I-MAB (IMAB) Dividend Payout Ratio : 0.00 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. I-MAB's Dividend Payout Ratio for the months ended in Jun. 2024 was 0.00.

The historical rank and industry rank for I-MAB's Dividend Payout Ratio or its related term are showing as below:

IMAB's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.48
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-12-13), the Dividend Yield % of I-MAB is 0.00%.

I-MAB's Dividends per Share for the months ended in Jun. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

I-MAB Dividend Payout Ratio Historical Data

The historical data trend for I-MAB's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Dividend Payout Ratio Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Dividend Payout Ratio	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of I-MAB's Dividend Payout Ratio

For the Biotechnology subindustry, I-MAB's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where I-MAB's Dividend Payout Ratio falls into.

I-MAB Dividend Payout Ratio Calculation

I-MAB's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-1.759
	=	N/A

I-MAB's Dividend Payout Ratio for the quarter that ended in Jun. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2024 )	/	Earnings per Share (Diluted) (Q: Jun. 2024 )
	=	0	/	0.092
	=	0.00

I-MAB (NAS:IMAB) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

I-MAB Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of I-MAB's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).